Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Cipla, Godrej...

    Cipla, Godrej recognised in Fortune Change the World list

    Written by savita thakur thakur Published On 2016-08-21T14:39:09+05:30  |  Updated On 21 Aug 2016 2:39 PM IST

    New York : India's pharmaceutical giant Cipla and consumer goods conglomerate Godrej have been recognised by Fortune magazine in a list of global firms changing the world for the good and having a positive social impact through their activities.


    Cipla is ranked 46th in the list of 50 followed by Godrej on the 48th spot, the only Indian companies in the list.


    The Fortune 2016 'Change the World' list recognises companies that have had a positive social impact through activities that are part of their core business strategy.


    The list has been topped by British pharma giant GlaxoSmithKline and includes Swiss food products major Nestle (5), India-born Ajay Banga-led Mastercard (7), US retail giant Walmart (15), China's ride-sharing company Didi Chuxing (30), India-born Indra Nooyi-led PepsiCo (38), Dutch beverages giant Heineken (43) and American motor company Tesla (50).


    Fortune lauded Cipla for "driving prices down for much-needed medications."


    "Cipla has made affordability and global accessibility to medicines the cornerstone of its business plan, reflecting the company's vision (of) 'None shall be denied'," it said.


    It added that Cipla has by far the world's widest range of antiretroviral (ARV) products approved by Food and Drug Administration and World Health Organisation for treating both children and adults suffering from HIV/AIDS, and also offers free ARV technology to all African countries wanting to produce their own drugs.


    On Cipla's horizon is low-cost pills to fight cancer.


    The company is investing in a drive to create "biosimilar" versions of certain pricey oncology drugs.


    "Expect heated intellectual-property debates and cheaper medicines," it said.


    On Godrej, Fortune said the company is "marketing a simple way to vanquish an insect enemy."


    Since 2010, the company has "flooded the market with eco-friendly products, taken giant strides in a carbon neutral, zero waste, and a renewable energy effort, and imparted skills training to more than 200,000 youth from marginalised communities in 142 cities," Fortune said.


    It added that Godrej's most important innovation may be its "fast card," an inexpensive mosquito-repelling device from the conglomerate's Godrej Consumer Products unit.


    Fortune said more businesses are taking on society's biggest problems and making money doing so.


    It assessed the companies on parameters of measurable social impact, business results and degree of innovation.

    antiretroviralChange the WorldCiplaGlaxoSmithKlineGodrejHIV AIDSWorld Health Organisation
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok